Dyslipidemia in patients with chronic kidney disease: etiology and management
Ivana Mikolasevic1, Marta Žutelija2, Vojko Mavrinac3
1Department of Gastroenterology; Department of Nephrology, Dialysis and Kidney Transplantation, UHC Rijeka.
Insights
Patients with chronic kidney disease (CKD) face higher cardiovascular risks due to dyslipidemia. While statins help some CKD patients, their benefit in dialysis patients remains uncertain, necessitating further research for effective treatments.
Area of Science:
- Nephrology
- Cardiology
- Clinical Lipidology
Background:
- Patients with chronic kidney disease (CKD), including those on dialysis or post-transplant, have a significantly elevated risk of cardiovascular disease (CVD) morbidity and mortality.
- Dyslipidemia, characterized by abnormal lipid profiles, is a prevalent risk factor for CVD development in this population, with specific alterations varying by renal function.
- Different stages of kidney disease and dialysis modalities (hemodialysis vs. peritoneal dialysis) are associated with distinct lipid profile changes, impacting cardiovascular risk.
Purpose of the Study:
- To review the complex lipid alterations in patients with chronic kidney disease across different stages and treatment modalities.
- To discuss the implications of these dyslipidemias for cardiovascular disease risk.
- To evaluate the current evidence for lipid-lowering therapies, particularly statins, in CKD patients and identify gaps in knowledge.
Main Methods:
- Literature review of studies examining lipid profiles in non-dialysis CKD, nephrotic syndrome, hemodialysis, peritoneal dialysis, and renal transplant recipients.
- Analysis of data from clinical trials investigating the efficacy of statins and other lipid-modifying agents in CKD populations.
- Synthesis of findings regarding the impact of renal impairment and dialysis on lipoprotein metabolism and cardiovascular outcomes.
Main Results:
- CKD patients exhibit diverse dyslipidemias, including low HDL, altered LDL, elevated triglycerides, and increased atherogenic remnant particles, varying with kidney function and dialysis type.
- Peritoneal dialysis patients often show more atherogenic lipid profiles compared to hemodialysis patients.
- While statins show benefit in mild-to-moderate CKD and transplant recipients, their efficacy in dialysis patients is uncertain, as suggested by recent trials (4D, AURORA, SHARP).
Conclusions:
- Dyslipidemia is a critical, multifaceted risk factor for cardiovascular disease in all stages of chronic kidney disease.
- Current evidence suggests a need for tailored management strategies, as lipid-lowering treatments effective in the general population may not translate directly to dialysis patients.
- Further research is essential to determine the optimal therapeutic approaches for managing dyslipidemia and reducing cardiovascular risk in patients undergoing dialysis.
Abstract:
Patients with chronic kidney disease (CKD), including those with end-stage renal disease, treated with dialysis, or renal transplant recipients have an increased risk for cardiovascular disease (CVD) morbidity and mortality. Dyslipidemia, often present in this patient population, is an important risk factor for CVD development. Specific quantitative and qualitative changes are seen at different stages of renal impairment and are associated with the degree of glomerular filtration rate declining. Patients with non-dialysis-dependent CKD have low high-density lipoproteins (HDL), normal or low total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol, increased triglycerides as well as increased apolipoprotein B (apoB), lipoprotein(a) (Lp (a)), intermediate- and very-low-density lipoprotein (IDL, VLDL; "remnant particles"), and small dense LDL particles. In patients with nephrotic syndrome lipid profile is more atherogenic with increased TC, LDL, and triglycerides. Lipid profile in hemodialysis (HD) patients is usually similar to that in non-dialysis-dependent CKD patients. Patients on peritoneal dialysis (PD) have more altered dyslipidemia compared to HD patients, which is more atherogenic in nature. These differences may be attributed to PD per se but may also be associated with the selection of dialytic modality. In renal transplant recipients, TC, LDL, VLDL, and triglycerides are elevated, whereas HDL is significantly reduced. Many factors can influence post-transplant dyslipidemia including immunosuppressive agents. This patient population is obviously at high risk; hence, prompt diagnosis and management are required to improve their clinical outcomes. Various studies have shown statins to be effective in the cardiovascular risk reduction in patients with mild-to-moderate CKD as well as in renal transplant recipients. However, according to recent clinical randomized controlled trials (4D, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Dialysis: an Assessment of Survival and Cardiovascular Events, and Study of Heart and Renal protection), these beneficial effects are uncertain in dialyzed patients. Therefore, further research for the most suitable treatment options is needed.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:18Chronic Kidney Disease IV: Nursing Management
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment